Biotricity, a medical diagnostic and consumer healthcare technology company dedicated to supplying innovative, biometric remote monitoring solutions, recently stated it has started expanding the capabilities of its remote patient monitoring (RPM) system with artificial intelligence (AI) to distinguish itself within the emergent remote monitoring marketplace.
The company is already involved with a proof of concept version of its RPM hardware with embedded AI. Biotricity plans the first commercial application to be the next generation of its Bioflux device. The company aims to file an extra 510(k) hardware clearance with the U.S. Food and Drug Administration (FDA) by Q3 in 2018, before introducing the next version. With Bioflux’s latest FDA clearance, development of AI and next generation hardware will happen while the existing version of Bioflux is in the marketplace.
“We plan on implementing artificial intelligence at the device level to maximize detection and accuracy while increasing efficiency,” said Waqaas Al-Siddiq, Founder and CEO of Biotricity. “We expect our next generation Bioflux device with artificial intelligence capabilities to be the first of its kind in the RPM marketplace.”
Remote patient monitoring is a multi-billion dollar market that is quickly increasing as technology becomes smaller and connectivity more economical. Biotricity plans to leverage its proprietary system to continuously innovate within the RPM sector.